Skip to content
Canine PeptideResearch peptides

GHK-Cu dosage for a medium breed

22–77 lb (10–35 kg)

The short answer

For a dog weighing 22–77 lb (10–35 kg), the dose of GHK-Cu reported in the literature is 1-1.5 mg per day injectable, or topical twice daily, given daily (injectable) / twice daily (topical), over 4-8 weeks injectable, topical ongoing. It is studied in this weight class primarily for wound healing, skin and coat, joint support. These figures are reported as published and are not recommendations — the dose for an individual dog must be set by a veterinarian who has examined the animal.

Typical breeds in this weight class

Beagle, Border Collie, Australian Shepherd, Bulldog, Cocker Spaniel and similarly sized dogs generally fall within 22–77 lb (10–35 kg). Weigh your dog rather than estimating — dosing is calculated per kilogram and an estimate that is out by a few kilos changes the figure materially, particularly at the smaller end.

Before dosing at all

⚠ Copper storage disease in predisposed breeds

Bedlington Terriers and certain Labrador Retriever lines carry an inherited copper storage disorder. In these dogs the injectable route risks hepatic copper accumulation. Hepatic function must be monitored, and the topical route is strongly preferred.

Common questions

How much GHK-Cu for a medium breed?+

For a dog in the 22–77 lb (10–35 kg) range, the reported dose is 1-1.5 mg per day injectable, or topical twice daily, given daily (injectable) / twice daily (topical), typically for 4-8 weeks injectable, topical ongoing. These figures are reported from the source literature and are not recommendations.

How often should a medium breed be given GHK-Cu?+

Daily (injectable) / twice daily (topical) is the reported frequency, over a course of 4-8 weeks injectable, topical ongoing. See the cycling guide for how breaks are structured.

Is GHK-Cu safe for a medium breed?+

GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.

References

  1. 1.CANINE STUDYCanapp SO, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14569578
  2. 2.Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227350
  3. 3.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMC4508379
  4. 4.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences, 2018. PMC6073405

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.